← board
CPMD
distress 5/10 · elevated risk$0.000%today-76% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+2%
Price & events
-47.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-8.7%
1W
-12.5%
1M
-46.2%
3M
-47.5%
6M
-30.0%
1Y
-81.7%
2Y
-95.3%
5Y
-99.6%
All
Overview
- Market Cap
- $1.42M
- Volume
- 24.11K
- 52 Week Range
- $0.00 – $0.01
- Total Shares
- 678.50M
- Float Shares
- 623.90M
- % Held by Insiders
- 6.76%
- % Held by Institutions
- 0.00%
- RVOL
- 0.26x
- Beta
- -1548.81
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- June 2025readoutcannabis · Second shipment to GermanySEC 8-K
- 2025-04-01partnershipcannabis · Fourth shipment to Israel in April 2025SEC 8-K
- 2025-03-01partnershipcannabis · First shipment to Germany completed in March 2025SEC 8-K
- 2024-01-01partnershipcannabis · First shipment to Israel in 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 678,501,405 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.